The purpose of this study is to investigate the efficacy and safety of recombinant erythropoietin-beta in the treatment of anemic patients with multiple myeloma (MM), low-grade non-Hodgkin's lymphoma (NHL), and chronic lymphocytic leukemia (CLL). From December 2005 to November 2006, the patients with MM, low-grade NHL, and CLL were enrolled in this study, male or female, aged > or = 18 years, transfusion-dependant, and receiving anti-neoplasia chemotherapy. Recombinant human erythropoietin-beta was used in this study with the dose initiated at 150 IU/kg, thrice a week, subcutaneously. The total treatment duration was 12 weeks. The primary endpoint of the study is response rate (RR), which is defined as hemoglobin increasing > or = 2 g/dL comparing to baseline level, or returning to normal range, without any transfusion within 6 weeks of evaluation. Fifty out of 82 (64.6%) patients enrolled in this study responded to the treatment and 29 patients had no response. Hypertension (12.2%) is the most common adverse effect; however, all the adverse events were mild, categorized in NCI grade I or II. We conclude that recombinant erythropoietin-beta was effective in the treatment of anemia of the patients with MM, NHL, and CLL, as well as it is well-tolerated.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12185-008-0130-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of a Combined Drug Approach on the Severity of Ischemia-Reperfusion Injury During Liver Transplant: A Randomized Clinical Trial.
JAMA Netw Open
February 2023
Laboratory of Abdominal Transplantation, Transplantation Research Group, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
Importance: In a porcine model of liver transplant, a combined drug approach that targeted the donor graft and graft recipient reduced ischemia-reperfusion injury, a major hurdle to the success of liver transplant.
Objective: To assess the effect of a clinical form of a perioperative combined drug approach delivered immediately before implantation to the procured liver and to the liver recipient on the degree of ischemia-reperfusion injury.
Design, Setting, And Participants: This unicentric, investigator-driven, open-label randomized clinical trial with 2 parallel arms was conducted in Belgium from September 2013 through February 2018, with 1-year follow-up.
Comparative effectiveness of erythropoietin alpha and beta in hemodialysis patients: a single-center prospective observational study.
J Community Hosp Intern Med Perspect
November 2021
Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Background And Objectives: Anemia is a prevalent complication endured by patients with chronic renal disease. Renal anemia also leads to the development of cardio-vascular complications. Epoetin alpha and beta are recombinant human erythropoietin prioritized for managing anemia in hemodialysis patients.
View Article and Find Full Text PDFTherapeutic Efficacy of Erythropoietin Alpha and Erythropoietin Beta in Anemia of Chronic Kidney Disease.
J Coll Physicians Surg Pak
December 2021
Department of Nephrology, The Kidney Centre Postgraduate Training Institute, Karachi, Pakistan.
Objective: To compare the effectiveness of erythropoietin alpha and erythropoietin beta in anemia management in the hemodialysis population.
Study Design: Quasi-experimental study.
Place And Duration Of Study: Department of Nephrology, The Kidney Center Postgraduate Training Institute (TKC-PGTI), Karachi, from December 2019 to July 2020.
Erythropoietin exerts direct immunomodulatory effects on the cytokine production by activated human T-lymphocytes.
Int Immunopharmacol
July 2016
Immanuel Kant Baltic Federal University, Kaliningrad, Russia. Electronic address:
The effect of erythropoietin-β (Epo-β) on the functional profile of activated human T-lymphocytes remains largely unknown, which hinders clinical application of Epo as an immunomodulatory agent. We studied the direct impact of Epo on the activation status of human T lymphocytes following activation by particles loaded with antibodies (Abs) against human CD2, CD3, and CD28. T cell activation was assessed by the surface expression of CD38 activation marker.
View Article and Find Full Text PDFErythropoietin reduces storage lesions and decreases apoptosis indices in blood bank red blood cells.
Rev Bras Hematol Hemoter
March 2016
Universidad Antonio Nariño, Bogotá, Colombia.
Background: Recent evidence shows a selective destruction of the youngest circulating red blood cells (neocytolysis) trigged by a drop in erythropoietin levels.
Objective: The aim of this study was to evaluate the effect of recombinant human erythropoietin beta on the red blood cell storage lesion and apoptosis indices under blood bank conditions.
Methods: Each one of ten red blood cell units preserved in additive solution 5 was divided in two volumes of 100mL and assigned to one of two groups: erythropoietin (addition of 665IU of recombinant human erythropoietin) and control (isotonic buffer solution was added).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!